In this context, it will be important to evaluate if tumor control could be further enhanced by combining Xcl1-SLP-Fc vaccination with immune checkpoint blockade, as demonstrated by us and others in pre-clinical and clinical settings (26, 34–36). This evidence concerns the gene XCL1 and neoplasm.